Document is current

Article History

Received: 19 May 2023

Accepted: 18 August 2023

First Online: 4 September 2023

Declarations

:

: MO have no conflict of interest. AK reports receiving personal fees from Daiichi Sankyo, Lilly, Ono, Taiho, BristolMyers Squibb, Merck Serono Biopharma, Sumitomo Dainippon, zymeworksand AstraZeneca outside the submitted work. HN have no conflict of interest. DK reports receiving honoraria from Takeda, Chugai, Lilly, MSD, Ono, Eisai, Taiho, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, Merckbiopharma, and Sysmex; receiving research funding from Ono, MSD, Novartis, Servier, Janssen, IQVIA, Syneoshealth, CIMIC, and Cimicshiftzero. SM has reports receiving honoraria from Merck Seronobiopharma: receiving research funding from Roche Diagnostics. YK reports receiving personal fees for advisory roles from Taiho, Takeda, and Boehringer Ingelheim; receiving honoraria from Taiho, Ono, Bayer, and Sanofi; receiving institutional grants or contracts from Taiho, Takeda, Ono, AbbVie, AstraZeneca, Boehringer Ingelheim, Incyte, Amgen, Chugai, GlaxoSmithKline, Genmab, Astellas, and Daiichi Sankyo. YN reports receiving honoraria from Chugai, Merck and Guardant Health AMEA; receiving research funding from Taiho, Chugai, Guardant Health, Genomedia, Daiichi Sankyo, Seagen and Roche Diagnostics. KS reports receiving personal fees for advisory roles from Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono, Merck Pharmaceutical, Taiho Pharmaceutical,Astellas, Novartis, AbbVie, GlaxoSmithKline, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Guardant Health Japan,and Janssen; receiving honoraria (lecture fee) from Takeda, Bristol-Myers Squibb and Janssen; and receiving research funding from Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, Merck Pharmaceutical, Medi Science, Eisai and Amgen, outside the submitted work.

Free to read: This content has been made available to all.